RG 1678

Known as: RG-1678, RG1678 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2014
012320102014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
IMPORTANCE In schizophrenia, the severity of negative symptoms is a key predictor of long-term disability. Deficient signaling… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2014
2014
Bitopertin (RG1678) is a glycine reuptake inhibitor in phase 3 trials for treatment of schizophrenia. Its clinical oral… (More)
  • table I
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
In this issue, Umbricht and colleagues1 reported improvement of negative symptomsof schizophrenia associatedwith 2 of 3 doses of… (More)
Is this relevant?
2013
2013
Deficient N-methyl-D-aspartate (NMDA) receptor transmission is thought to underlie schizophrenia. An approach for normalizing… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
We characterize a novel radioligand for the glycine transporter type 1 (GlyT1), [(11)C]RO5013853, in humans. Ten healthy male… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
BACKGROUND Bitopertin (RG1678) is a glycine reuptake inhibitor currently in phase 3 trials for treatment of schizophrenia. This… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2013
2013
A specific positron emission tomography (PET) radiotracer for the glycine transporter type 1 (GlyT1) would constitute an imaging… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Dysfunctional N-methyl-d-aspartate (NMDA) receptor neurotransmission has been implicated in the pathophysiology of schizophrenia… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
2012
2012
BACKGROUND Bitopertin (RG1678) is a selective glycine reuptake inhibitor currently in Phase III development for the treatment of… (More)
Is this relevant?
2010
2010
The GlyT1 transporter has emerged as a key novel target for the treatment of schizophrenia. Herein, we report on the optimization… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?